A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.

Authors :: Nakamura R
La Rosa C
Yang D
Hill JA
Rashidi A
Choe H
Zhou Q
Lingaraju CR
Kaltcheva T
Longmate J
Drake J
Slape C
Duarte L
Al Malki MM
Pullarkat VA
Aribi A
Devine S
Verneris MR
Miller JS
Forman SJ
Aldoss I
Diamond DJ
Source :: Haematologica [Haematologica] 2024 Jun 01; Vol. 109 (6), pp. 1994-1999. Date of Electronic Publication: 2024 Jun 01.
Publication Year :: 2024

Subjects :: Adult
Aged
Female
Humans
Male
Middle Aged
Transplantation, Homologous
Virus Activation immunology
Cytomegalovirus immunology
Cytomegalovirus Infections prevention & control
Cytomegalovirus Infections immunology
Cytomegalovirus Infections etiology
Cytomegalovirus Vaccines immunology
Hematopoietic Stem Cell Transplantation adverse effects

Full Text Access

Tools